Research Progress on Interstitial Lung Disease Complicated with Gastroesophageal Reflux Disease
DOI:
https://doi.org/10.62051/3xcs0g24Keywords:
Interstitial lung disease; Gastroesophageal reflux disease; Comorbidity; Reflux.Abstract
Interstitial lung disease (ILD) and gastroesophageal reflux disease (GERD) are highly comorbid and closely related in pathophysiology. Epidemiological data show that the prevalence of GERD in patients with ILD is significantly higher than that in the general population. ILD can induce reflux disease through abnormal respiratory mechanics, dysfunction of the diaphragm and esophagus, and increased abdominal pressure caused by cough. Microaspiration resulting from reflux can irritate lung tissue, aggravate pulmonary inflammation and fibrosis progression, and affect patients’ clinical symptoms, quality of life, and prognosis after lung transplantation. Clinically, a multi-level treatment strategy has been established for comorbid conditions. Non-pharmacological interventions can reduce reflux triggers. The use of acid-suppressive drugs requires distinguishing indications for prophylactic medication according to disease types. Surgery and traditional Chinese medicine can be selected appropriately based on the disease condition. Standardized treatment of GERD can reduce lung tissue injury, delay the progression of ILD, and improve the overall prognosis of patients. Clinically, relevant guidelines should be followed, and diagnosis and treatment strategies should be formulated according to individual conditions to improve the comprehensive intervention effect of comorbidities.
Downloads
References
[1] Shah Gupta, R., et al., Incidence and prevalence of interstitial lung diseases worldwide: a systematic literature review. BMJ Open Respir Res, 2023. 10(1). DOI: https://doi.org/10.1136/bmjresp-2022-001291
[2] Maher, T.M., Interstitial Lung Disease: A Review. Jama, 2024. 331(19): p. 1655-1665. DOI: https://doi.org/10.1001/jama.2024.3669
[3] Clarrett, D.M. and C. Hachem, Gastroesophageal Reflux Disease (GERD). Mo Med, 2018. 115(3): p. 214-218.
[4] Jafri, S., et al., Epidemiology and Clinico-radiological features of Interstitial Lung Diseases. Pak J Med Sci, 2020. 36(3): p. 365-370. DOI: https://doi.org/10.12669/pjms.36.3.1046
[5] Qi, J., et al., [The relationship between idiopathic pulmonary fibrosis and gastroesophageal reflux disease]. Zhonghua Nei Ke Za Zhi, 2015. 54(8): p. 695-8.
[6] 6. Moon, J.Y., M. Beenken, and T. Moua, Impact of Medical Comorbidities on Respiratory-Related Patient-Reported Outcome Measures in Fibrotic Interstitial Lung Disease. J Clin Med, 2026. 15(3). DOI: https://doi.org/10.3390/jcm15031051
[7] Baqir, M., et al., Idiopathic pulmonary fibrosis and gastroesophageal reflux disease: A population-based, case-control study. Respir Med, 2021. 178: p. 106309. DOI: https://doi.org/10.1016/j.rmed.2021.106309
[8] Wang, X., et al., Association of gastroesophageal reflux disease with the incidence of pulmonary disease. Front Cell Dev Biol, 2025. 13: p. 1552126. DOI: https://doi.org/10.3389/fcell.2025.1552126
[9] Joshua, J., et al., Selective dysfunction of the crural diaphragm in patients with chronic restrictive and obstructive lung disease. Neurogastroenterol Motil, 2024. 36(1): p. e14699. DOI: https://doi.org/10.1111/nmo.14699
[10] Alghubari, A., et al., Associations Between Esophageal Motility, Reflux, and Lung Mechanics and Function Are Disease-Specific, Both Between and Within Restrictive and Obstructive Lung Disease. Clin Transl Gastroenterol, 2025. 16(9): p. e00874. DOI: https://doi.org/10.14309/ctg.0000000000000874
[11] Lee, A.L. and R.S. Goldstein, Gastroesophageal reflux disease in COPD: links and risks. Int J Chron Obstruct Pulmon Dis, 2015. 10: p. 1935-49. DOI: https://doi.org/10.2147/COPD.S77562
[12] Molina-Molina, M., The relationship between gastro-oesophageal reflux and pulmonary fibrosis: a never-ending story. Eur Respir J, 2023. 61(5). DOI: https://doi.org/10.1183/13993003.00566-2023
[13] Ala Çitlak, F.S., et al., Investigation of pepsin levels in bronchial lavage in patients with interstitial lung disease and chronic cough. Respir Med, 2024. 233: p. 107781. DOI: https://doi.org/10.1016/j.rmed.2024.107781
[14] Khor, Y.H., et al., Epidemiology and Prognostic Significance of Cough in Fibrotic Interstitial Lung Disease. Am J Respir Crit Care Med, 2024. 210(8): p. 1035-1044. DOI: https://doi.org/10.1164/rccm.202311-2101OC
[15] Brown, A.W., H. Kaya, and S.D. Nathan, Lung transplantation in IIP: A review. Respirology, 2016. 21(7): p. 1173-84. DOI: https://doi.org/10.1111/resp.12691
[16] Mullholand, J.B., C.E. Grossman, and A. Perelas, Non-Pharmacological Management of Idiopathic Pulmonary Fibrosis. J Clin Med, 2025. 14(4). DOI: https://doi.org/10.3390/jcm14041317
[17] Sato, R., et al., Antitussive Effect of a Chest Band in Patients with Interstitial Lung Disease: The Preliminary Results from a Pre-post Intervention Study. Intern Med, 2021. 60(23): p. 3701-3707. DOI: https://doi.org/10.2169/internalmedicine.6716-20
[18] Raghu, G., et al., Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med, 2022. 205(9): p. e18-e47.
[19] Quinlivan, A., et al., The impact of gastroesophageal reflux disease and its treatment on interstitial lung disease outcomes. Arthritis Res Ther, 2024. 26(1): p. 124. DOI: https://doi.org/10.1186/s13075-024-03355-0
[20] Kreuter, M., et al., Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis. Rheumatology (Oxford), 2023. 62(9): p. 3067-3074. DOI: https://doi.org/10.1093/rheumatology/kead023
[21] Nelkine, L., et al., Role of antioxidants in the treatment of gastroesophageal reflux disease-associated idiopathic pulmonary fibrosis. Curr Opin Pulm Med, 2020. 26(4): p. 363-371. DOI: https://doi.org/10.1097/MCP.0000000000000684
[22] Senay, A.N., et al., Protective effects of antireflux surgery on lung function in patients with interstitial lung disease. Surg Endosc, 2025. 39(9): p. 6037-6042. DOI: https://doi.org/10.1007/s00464-025-11943-7
[23] Ruaro, B., et al., Gastroesophageal Reflux Disease in Idiopathic Pulmonary Fibrosis: Viewer or Actor? To Treat or Not to Treat? Pharmaceuticals (Basel), 2022. 15(8). DOI: https://doi.org/10.3390/ph15081033
[24] Lin QM, Chen F, Zhang W. Traditional Chinese Medicine understanding of gastroesophageal reflux disease complicated with interstitial lung disease based on the "Chest Binding Syndrome" in Treatise on Febrile Diseases. Liaoning Journal of Traditional Chinese Medicine. 2022;49(2):40-43.
[25] Zhou HW, Yu HY, Wang CX. Exploration on the treatment of idiopathic pulmonary fibrosis combined with gastroesophageal reflux guided by the theory of "acrid opening and bitter descending". China Medical Herald. 2021;18(17):130-133.
[26] Chang QY, et al. Clinical experience of replenishing and regulating qi therapy for idiopathic pulmonary fibrosis complicated with gastroesophageal reflux disease. China Journal of Traditional Chinese Medicine and Pharmacy. 2025;40(2):699-702.
[27] Zhou, J.C., et al., Relationship Between Esophageal Disease and Pulmonary Fibrosis. Dig Dis Sci, 2023. 68(4): p. 1096-1105. DOI: https://doi.org/10.1007/s10620-023-07908-2
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Transactions on Materials, Biotechnology and Life Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
